Single dose malaria drug could simplify treatment worldwide in medical breakthrough
Global statistics from 2024 show an estimated 282 million malaria cases and 610,000 deaths, with numbers escalating partly due to increasing resistance to…
- Center-left1
- Center-right1
- Right1
1 agency rewrite / co-publication detected
Summary
Global statistics from 2024 show an estimated 282 million malaria cases and 610,000 deaths, with numbers escalating partly due to increasing resistance to current drugs. Paul Willis, MMV's vice president of drug discovery and preclinical safety, said: "Novel treatment and prevention regimens are urgently needed with simplified dosing to enable effective case management and to support long-term malaria control and elimination goals.". Conducted by pharmaceutical firm Merck as part of the PAMAfrica consortium, the trial was co-funded by the EDCTP2 Programme, with support from the European Union and the Swedish International Development Co-operation Agency.
Furthermore, Prof Gilbert said: "The benefits of this compound are not only that it looks to be effective, with a good benefit/risk profile, but it can also be delivered in a single dose, which is an important factor when you are treating a disease that occurs commonly in areas where consistent delivery of healthcare can be challenging." Following scientific and financial support from MMV, the organisation now plans to progress cabamiquine-pyronaridine into further development. Malaria is a severe mosquito-borne illness that mostly affects people living in tropical countries. Researchers have welcomed a new antimalarial compound as "an exciting step forward" in the global fight against the disease.
In addition, Early-stage trial results showed that when combined with the existing drug pyronaridine, the treatment proved effective and demonstrated a favourable safety profile in adults and teenagers.
Cross-referenced from 3 sources.
Factual coreconfirmed by several independent voices
Global statistics from 2024 show an estimated 282 million malaria cases and 610,000 deaths, with numbers escalating partly due to increasing resistance to current drugs.
reliability moderate2/3 sourcesPaul Willis, MMV's vice president of drug discovery and preclinical safety, said: "Novel treatment and prevention regimens are urgently needed with simplified dosing to enable effective case management and to support long-term malaria control and elimination goals."
reliability moderate2/3 sourcesConducted by pharmaceutical firm Merck as part of the PAMAfrica consortium, the trial was co-funded by the EDCTP2 Programme, with support from the European Union and the Swedish International Development Co-operation Agency.
reliability low1/2 sourcesProf Gilbert said: "The benefits of this compound are not only that it looks to be effective, with a good benefit/risk profile, but it can also be delivered in a single dose, which is an important factor when you are treating a disease that occurs commonly in areas where consistent delivery of healthcare can be challenging." Following scientific and financial support from MMV, the organisation now plans to progress cabamiquine-pyronaridine into further development.
reliability low1/2 sourcesMalaria is a severe mosquito-borne illness that mostly affects people living in tropical countries.
reliability low1/2 sourcesResearchers have welcomed a new antimalarial compound as "an exciting step forward" in the global fight against the disease.
reliability moderate2/2 sources
Reported detailssecondary facts, each attributed to its source
Early-stage trial results showed that when combined with the existing drug pyronaridine, the treatment proved effective and demonstrated a favourable safety profile in adults and teenagers.
according to The IndependentScientists have hailed a new antimalarial compound as “an exciting step forward” in the worldwide fight against the disease.
according to Evening Standard
Disputedincompatible versions — to verify
No factual contradiction detected between sources.
Framing by sidesame fact, different words — loaded terms highlighted
No notable framing divergence.
Blind spotwhat one side keeps silent
Conducted by pharmaceutical firm Merck as part of the PAMAfrica consortium, the trial was co-funded by the EDCTP2 Programme, with support…
omitted byRight sidecovered byLeft sideRight sideProf Gilbert said: "The benefits of this compound are not only that it looks to be effective, with a good benefit/risk profile, but it can…
omitted byRight sidecovered byLeft sideRight sideMalaria is a severe mosquito-borne illness that mostly affects people living in tropical countries.
omitted byRight sidecovered byLeft sideRight sideResearchers have welcomed a new antimalarial compound as "an exciting step forward" in the global fight against the disease.
omitted byRight sidecovered byLeft sideRight side
